By Matt Fair (May 26, 2015, 6:56 PM EDT) -- Bolstered by a March verdict clearing a Johnson & Johnson unit of liability despite a finding that its Risperdal warning labels were inadequate, the company is likely to keep the focus on whether the antipsychotic drug actually caused a plaintiff's abnormal breast growth as another trial begins Wednesday in Philadelphia.
Experts say that muddying the waters for jurors when it comes to the causal link between Risperdal and abnormal breast growth in plaintiff Christopher Walker, who is the third Risperdal patient whose claims are to be decided by a Philadelphia jury, will likely prove easier for the Johnson & Johnson unit...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!